Clinical Applications

Clinuvel is currently trialing afamelanotide in a range of light and UV related skin disorders (photodermatoses). It is proposed that afamelanotide will provide prophylactic treatment to patients suffering from these disorders by stimulating melanin to act as a photoprotective filtering the impact of UV to the skin.

Clinuvel's current clinical focus is on:

• Erythropoietic Protoporphyria (EPP) - absolute sun intolerance, intolerable pain suffered when exposed to light by between one in 200,000 and one in 750,000.
  Read more about EPP on Clinuvel Photoprotection.
  Find more information about EPP trials on the ANZCTR site.
• Squamous Cell Carcinoma (SCC) - non-melanoma skin cancers – and Actinic Keratosis (AK), a precursor to skin cancers, in organ transplant recipients (OTRs).
  Read more about SCC on Clinuvel Photoprotection.
  Read more about AK on Clinuvel Photoprotection.
  More information on Clinuvel’s AK/SCC trials with organ transplant recipients is available on the ClinicalTrials.gov website.
• Polymorphous Light Eruption (PLE/PMLE) – likened to sun poisoning. Suffered by 10-20% of population.
  Read more about PLE on Clinuvel Photoprotection.
  Find more information about PLE trials on the ClinicalTrials.gov site.
• Solar Urticaria (SU) – (acute) anaphylactic reaction to sun.
  Read more about SU on Clinuvel Photoprotection.
• Phototoxicity associated with Photodynamic Therapy (PDT) for cancer – a debilitating photosensitivity to sunlight and artificial light (skin and eyes) that can last up to 90 days after PDT treatment.
  Read more about PDT on Clinuvel Photoprotection.

On February 10 2010, Clinuvel announced a strategic focus of its program for afamelanotide on EPP, AK and PLE. Clinuvel's current resources focus on the development of afamelanotide for these conditions. Read the company's release here